Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
49 studies found for:    myeloma and carfilzomib | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib
Conditions: Relapse Multiple Myeloma;   Refractory Multiple Myeloma
Intervention: Drug: Carfilzomib
2 Recruiting A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib;   Drug: Cyclophosphamide;   Drug: Dexamethasone
3 Recruiting Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients
Condition: Multiple Myeloma
Intervention: Drug: CARFILZOMIB, CYCLOPHOSPHAMIDE, DEXAMETHASONE
4 Recruiting A Phase I Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed and/or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Panobinostat;   Drug: Carfilzomib;   Drug: Dexamethasone
5 Recruiting Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bendamustine;   Drug: Carfilzomib;   Drug: Dexamethasone
6 Not yet recruiting Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib;   Drug: Dexamethasone;   Drug: Prednisone;   Drug: Methylprednisolone
7 Recruiting Arry-520 + Carfilzomib for Multiple Myeloma (MM)
Condition: Myeloma
Interventions: Drug: Arry-520;   Drug: Carfilzomib;   Drug: Dexamethasone;   Drug: Filgrastim
8 Recruiting Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: bortezomib;   Drug: lenalidomide;   Drug: dexamethasone;   Drug: carfilzomib;   Procedure: quality-of-life assessment;   Other: laboratory biomarker analysis
9 Recruiting Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: carfilzomib and panobinostat
10 Recruiting A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib;   Drug: Cyclophosphamide;   Drug: Dexamethasone
11 Recruiting S1304, Testing Two Doses of Carfilzomib With Dexamethasone for Relapsed or Refractory Myeloma
Condition: Relapsed or Refractory Multiple Myeloma
Interventions: Drug: dexamethasone;   Drug: carfilzomib
12 Recruiting Carfilzomib Plus Panobinostat in Relapsed/Refractory Multiple Myeloma (MM)
Condition: Myeloma
Interventions: Drug: Carfilzomib;   Drug: Panobinostat
13 Recruiting Ph 1b, Carfilzomib, Bendamustine, Dexamethasone in Multiple Myeloma
Condition: Myeloma
Interventions: Drug: Carfilzomib;   Drug: Bendamustine;   Drug: Dexamethasone
14 Recruiting A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone
15 Recruiting A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib;   Drug: Pomalidomide;   Drug: Dexamethasone
16 Recruiting Study of the Bruton's Tyrosine Kinase Inhibitor in Combination With Carfilzomib (Kyprolis™), in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Ibrutinib;   Drug: Carfilzomib;   Drug: Placebo;   Drug: Dexamethasone
17 Recruiting Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Cohort 1: Carfilzomib 15 mg/m2;   Drug: Cohort 2: Carfilzomib 20 mg/m2;   Drug: Cohort 3: Carfilzomib 27 mg/m2
18 Recruiting Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: dexamethasone;   Drug: carfilzomib;   Drug: lenalidomide;   Procedure: autologous hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
19 Recruiting Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: carfilzomib;   Drug: melphalan;   Procedure: autologous bone marrow transplantation;   Procedure: autologous hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
20 Recruiting A Single Arm Study of Carfilzomib in Transplant Eligible High Risk Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Carfilzomib, Cyclophosphamide, Dexamethasone

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years